Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists

被引:23
|
作者
Huang, CQ
Wilcoxen, K
McCarthy, JR
Haddach, M
Webb, TR
Gu, J
Xie, YF
Grigoriadis, DE
Chen, C
机构
[1] Neurocrine Biosci Inc, Dept Med Chem, San Diego, CA 92121 USA
[2] Neurocrine Biosci Inc, Dept Pharmacol, San Diego, CA 92121 USA
关键词
D O I
10.1016/S0960-894X(03)00684-X
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 4-substituted 8-aryl-2-methylquinolines 4 was designed and synthesized as highly potent antagonists for the human CRF1 receptor. This series of compounds displayed parallel SAR to other bicyclic systems such as pyrazolo[l,5-a]pyrimidines, with several compounds possessing low nanomolar binding affinity. In addition to the high potency, the basicity of this 4-aminoquinoline core may offer CRF1 antagonists with lower lipophilicity. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3375 / 3379
页数:5
相关论文
共 50 条
  • [1] Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor1 (CRF1) receptor antagonists
    Huang, CQ
    Grigoriadis, DE
    Liu, ZY
    McCarthy, JR
    Ramphal, J
    Webb, T
    Whitten, JP
    Xie, MY
    Chen, C
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) : 2083 - 2086
  • [2] Design and synthesis of tricyclic corticotropin-releasing factor-1 (CRF1) antagonists
    Williams, JP
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2511 - U2512
  • [3] Selective impairment of corticotropin-releasing factor1 (CRF1) receptor-mediated function using CRF coupled to saporin
    Maciejewski-Lenoir, D
    Heinrichs, SC
    Liu, XJ
    Ling, N
    Tucker, A
    Xie, Q
    Lappi, DA
    Grigoriadis, DE
    ENDOCRINOLOGY, 2000, 141 (02) : 498 - 504
  • [4] Pyrazinones as corticotropin releasing factor (CRF1) receptor antagonists.
    Arvanitis, AG
    Arnold, CR
    Fitzgerald, LW
    Zaczek, R
    Olson, RE
    Trainor, GL
    Robertson, DW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U949 - U950
  • [5] Design, synthesis and structure activity relationship (SAR) of 8-arylquinoline corticotropin releasing factor 1 (CRF1) receptor antagonists.
    Huang, CQ
    Haddach, M
    Chen, C
    Wilcoxen, KM
    Xie, YF
    Grigoriadis, D
    De Souza, E
    McCarthy, JR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 217 : U1155 - U1155
  • [6] Heterocyclic triazolopyridines and triazolopyrimidines as corticotropin releasing factor (CRF1) receptor antagonists.
    Arvanitis, AG
    Bakthavatchalam, R
    Beck, JP
    Rescinito, JT
    Arnold, CR
    Zaczek, R
    Gilligan, PJ
    Olson, RE
    Robertson, DW
    Fitzgerald, LW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U948 - U949
  • [7] Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor
    Hoare, Sam R. J.
    Brown, Brock T.
    Santos, Mark A.
    Malany, Siobhan
    Betz, Stephen F.
    Grigoriadis, Dimitri E.
    BIOCHEMICAL PHARMACOLOGY, 2006, 72 (02) : 244 - 255
  • [8] Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists
    Hartz, Richard A.
    Ahuja, Vijay T.
    Schmitz, William D.
    Molski, Thaddeus F.
    Mattson, Gail K.
    Lodge, Nicholas J.
    Bronson, Joanne J.
    Macor, John E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (06) : 1890 - 1894
  • [9] The distribution of corticotropin-releasing factor (CRF), CRF binding sites and CRF1 receptor mRNA in the mouse cerebellum
    King, JS
    Madtes, P
    Bishop, GA
    Overbeck, TL
    CEREBELLUM: FROM STRUCTURE TO CONTROL, 1997, 114 : 55 - 66
  • [10] Predictive QSAR modeling of substituted Phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists: computational approach
    Sharma M.C.
    Netw. Model. Anal. Health Informatics Bioinformatics, 1 (1-15): : 1 - 15